DUX4 Antisense Screening and Suppression for FSHD

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic methods for Facioscapulohumeral dystrophy (FSHD) are inadequate, particularly for FSHD2, and there is a lack of effective treatments targeting the underlying molecular mechanism of the disease, which is linked to DUX4 expression.

Innovation Solution

A method for screening FSHD using genomic DNA analysis to detect polymorphisms in the DUX4 gene, including the use of polynucleotide probes and primers that specifically hybridize to the DUX4 exon 3 region, and a kit for detecting DUX4-fl polypeptide or mRNA, along with therapeutic agents to inhibit DUX4 expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If pulse-field gel electrophoresis and Southern blotting are used to detect D4Z4 repeat contraction, then diagnostic accuracy for FSHD1 is improved, but device complexity and ease of operation deteriorate

Engineering Contradiction:

Improvediagnostic accuracyVSAvoidcomplexity of diagnostic procedure

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent extracts the diagnostic function from complex molecular biology procedures (pulse-field gel electrophoresis and Southern blotting) and implements it through a simplified PCR-based method that detects specific genetic markers associated with D4Z4 repeat contraction, thereby maintaining diagnostic accuracy while reducing procedural complexity

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent replaces the mechanical and manual processes of gel electrophoresis and blotting with a molecular biology-based PCR amplification and detection system, substituting complex physical separation methods with targeted genetic marker detection that is both accurate and easier to standardize

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Adaptability or versatility

If no commercially available diagnostic tests exist for FSHD2, then adaptability to different FSHD types is improved, but ease of operation and reliability deteriorate

Engineering Contradiction:

Improveapplicability to FSHD typesVSAvoidreliability of diagnosis

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent creates a universal diagnostic approach that can identify genetic markers common to both FSHD1 and FSHD2 through PCR detection of polymorphisms in the D4Z4 repeat region and flanking sequences, enabling a single method to serve multiple diagnostic purposes across different FSHD subtypes

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent performs preliminary identification of specific genetic polymorphisms and haplotypes associated with FSHD susceptibility before clinical diagnosis, allowing for pre-screening and risk assessment that improves both reliability and adaptability across different patient populations

Inventive Principle:

Principle #10Preliminary action

3Loss of information

If DUX4-fl expression is not suppressed, then understanding of disease mechanism is improved, but object-generated harmful factors worsen

Engineering Contradiction:

Improvedisease mechanism understandingVSAvoidapoptotic cell death

Core Design Contradiction:

Loss of informationVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful effect of DUX4-fl overexpression (apoptotic cell death) into a beneficial diagnostic tool by using the presence and level of DUX4-fl expression as a marker for FSHD diagnosis and risk assessment, while simultaneously developing methods to suppress this expression for therapeutic benefit

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS12624396B2Methods for alleviating facioscapulohumeral dystrophy (FSHD) by an antisense nucleic acid molecule inhibiting the expression of double homeobox 4 (DUX4)

Publication Date: 2026.05.12 FRED HUTCHINSON CANCER CENT

AI summary

In one aspect, the invention provides a method of screening a human subject to determine if said subject has a genetic predisposition to develop, or is suffering from Facioscapulohumeral Dystrophy (FSHD), said method comprising: (a) providing a biological sample comprising genomic DNA from the subject; and (b) analyzing the portion of the genomic DNA in the sample corresponding to the distal D4Z4-pLAM region on chromosome 4 and determining the presence or absence of a polymorphism resulting in a functional polyadenylation sequence operationally linked to exon 3 of the DUX4 gene.